Shares of Moderna Inc. were up 1.9% in premarket trading on Thursday after the company said it has finalized the Phase 3 study protocol for its COVID-19 vaccine candidate. However, the Phase 2 trial, which began dosing patients less than two weeks ago, has not been completed.
Trending:
Moderna's stock gains on detailed plans for Phase 3 study of COVID-19 vaccine